CENTOGENE to Report First Half 2020 Financial Results on September 23, 2020
CAMBRIDGE, Mass., and ROSTOCK, Germany & BERLIN, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that it will issue a press release reporting its financial results for the six months ended June 30, 2020 on Wednesday, September 23, 2020, and will host a conference call to discuss these results at 8 a.m. ET that day.
Participants may access the conference call on September 23, 2020 by dialing U.S. toll free +1 877 870 9135 or U.K. +44 (0) 844 481 9752 up to 10 minutes prior to the start of the call and by providing the conference ID number 9368556. The webcast of the conference call and the related earnings presentation will be available on the Investor Relations page of the company’s website at http://investors.centogene.com.
CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 3.0 billion weighted data points from over 530,000 patients representing over 120 different countries as of March 31, 2020.
Important Notice and Disclaimer
Media Contact: CENTOGENE Sun Kim Chief Strategy and Investor Relations Officer firstname.lastname@example.org FTI Consulting Bridie Lawlor +1.917.929.5684 email@example.com
Session Details TBA
Millimeter Wave: The Need for Speed
Protecting Critical Infrastructure with Epic Security